Login / Signup

Dipeptidyl peptidase 4 inhibitors attenuates the decline of skeletal muscle mass in patients with type 2 diabetes.

Ryotaro BouchiTatsuya FukudaTakato TakeuchiYujiro NakanoMasanori MurakamiIsao MinamiHajime IzumiyamaKoshi HashimotoTakanobu YoshimotoYoshihiro Ogawa
Published in: Diabetes/metabolism research and reviews (2017)
Our data suggest the potential of DPP4i to prevent the progressive loss of muscle mass with ageing in patients with type 2 diabetes.
Keyphrases
  • skeletal muscle
  • multiple sclerosis
  • electronic health record
  • insulin resistance
  • human health
  • metabolic syndrome
  • climate change